Results 11 to 20 of about 83,999 (309)
Corticosteroids for Diabetic Macular Edema
Taiwan Journal of Ophthalmology, 2019 Diabetic macular edema (DME) is a chronic condition with a multifactorial pathogenesis. Vascular endothelial growth factor (VEGF) and several inflammatory mediators are upregulated in eyes with DME.
Jorge Chawan-Saad +3 more
semanticscholar +5 more sources
Nepalese Journal of Ophthalmology, 2016 Diabetic retinopathy is a frequent manifestation of long standing diabetes mellitus. According to the World Health Organization diabetes affects nine percent of the adult population worldwide (Diabetes Fact Sheet, 2015). Of all of the common diseases of the eye, diabetic retinopathy has a great impact on the working age population and therefore ...
Susan B. Bressler, Adrienne W. Scott
+9 more sources
Saudi Journal of Ophthalmology, 2009 A variety of treatment options are available for the treatment of diabetic macular edema. They include laser photocoagulation, anti-VEGF drugs, intravitreal steroids, and vitrectomy with or without release of vitreoretinal traction. A full understanding of the physiological mechanisms of these treatment modalities allows sensible combination of ...
S.P. Chaudhary +3 more
+12 more sources
Ophthalmology, 2012 Diabetic macular edema (DME) remains the most common cause of vision loss among diabetic patients. New understanding of the underlying pathophysiology has interest in the potential benefits of the specific pharmacologic therapy, such as treatment with intraocular steroids, anti-vascular endothelial growth factor (VEGF), and protein kinase C-beta (PKCβ)
Oana Toma +6 more
+11 more sources
International Journal of Molecular Sciences, 2022 Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries.
Sławomir Liberski +2 more
semanticscholar +1 more source
Asia-Pacific Journal of Ophthalmology, 2020 Diabetic macular edema (DME) accounts for the majority of decreased vision related to diabetic retinopathy and is a leading cause of vision loss in developed countries. Role of vitrectomy for DME has been proposed for several decades. After introduction of anti-vascular endothelial growth factor (VEGF) treatment, demands for the other treatments, such ...
Sung Who Park, Ik Soo Byon, Ji Eun Lee
openaire +4 more sources
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema
Cells, 2022 Diabetic macular edema (DME) is a major ocular complication of diabetes mellitus (DM), leading to significant visual impairment. DME’s pathogenesis is multifactorial.
M. Z. Chauhan +4 more
semanticscholar +1 more source
CHOROIDAL THICKNESS IN PATIENTS WITH DIABETIC MACULAR EDEMA
Pakistan Armed Forces Medical Journal, 2021 Objective: To evaluate central macular thickness and choroidal thickness in patients with macular edema due to diabetic retinopathy versus controls. Study Design: Cross-sectional comparative study.
Amash Aqil +3 more
doaj +1 more source
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
New England Journal of Medicine, 2022 BACKGROUND In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is ...
Chirag D. Jhaveri +15 more
semanticscholar +1 more source
Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema
Pharmaceutics, 2022 Diabetic retinopathy (DR) is one of the leading causes of blindness worldwide. Multiple treatment options have been used over time to attempt to modify the natural progression of the disease in both proliferative diabetic retinopathy (PDR) and diabetic ...
J. H. Gonzalez-Cortes +8 more
semanticscholar +1 more source